Given that IDH mutations may adversely affect outcome in MDS are relatively easy to assess at diagnosis, examining IDH mutations in MDS may enhance the current prognostic scoring systems and guide patient-specific treatment in MDS. This evidence concerns the gene IDH1 and myelodysplastic syndrome.